MEI Pharma Announces Board Changes and New CMO
Ticker: LITS · Form: 8-K · Filed: Aug 2, 2024 · CIK: 1262104
| Field | Detail |
|---|---|
| Company | Mei Pharma, INC. (LITS) |
| Form Type | 8-K |
| Filed Date | Aug 2, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.00000002, $475, $550,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
Related Tickers: MEIP
TL;DR
MEI Pharma shakes up board, names new CMO, and rejigs CEO pay.
AI Summary
MEI Pharma, Inc. announced on July 31, 2024, a series of significant corporate changes. These include the departure of Director Kevin R. Lind, the election of new Directors Dr. David M. Erbe and Dr. David J. Earp, and the appointment of Dr. Erbe as Chief Medical Officer. Additionally, the company entered into a new compensatory arrangement with its Chief Executive Officer, Daniel Gold, effective July 31, 2024.
Why It Matters
The changes in leadership and board composition suggest a strategic shift or response to recent performance or future plans for MEI Pharma.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate underlying issues or significant strategic shifts, introducing uncertainty.
Key Players & Entities
- MEI Pharma, Inc. (company) — Registrant
- Kevin R. Lind (person) — Departing Director
- Dr. David M. Erbe (person) — Newly Elected Director and Chief Medical Officer
- Dr. David J. Earp (person) — Newly Elected Director
- Daniel Gold (person) — Chief Executive Officer
- July 31, 2024 (date) — Effective date of changes
FAQ
Who has departed from the MEI Pharma board of directors?
Director Kevin R. Lind has departed from the MEI Pharma board of directors as of July 31, 2024.
Who are the new directors elected to the MEI Pharma board?
Dr. David M. Erbe and Dr. David J. Earp were elected as new directors to the MEI Pharma board.
What new role has Dr. David M. Erbe taken on?
Dr. David M. Erbe has been appointed as the Chief Medical Officer of MEI Pharma.
When were these changes effective?
The reported changes, including director departures, elections, and the new CMO appointment, were effective as of July 31, 2024.
Has the compensatory arrangement for the CEO changed?
Yes, MEI Pharma entered into a new compensatory arrangement with its Chief Executive Officer, Daniel Gold, effective July 31, 2024.
Filing Stats: 1,542 words · 6 min read · ~5 pages · Grade level 12.7 · Accepted 2024-08-02 16:05:09
Key Financial Figures
- $0.00000002 — nge on which registered Common Stock, $0.00000002 par value MEIP The Nasdaq Stock Mar
- $475 — Company will pay each of the Executives $475 per hour. Each Executive will also each
- $550,000 — dum increases Mr. File's base salary to $550,000 and increases Mr. File's annual bonus o
Filing Documents
- meip-20240731.htm (8-K) — 48KB
- 0000950170-24-089939.txt ( ) — 158KB
- meip-20240731.xsd (EX-101.SCH) — 23KB
- meip-20240731_htm.xml (XML) — 4KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEI Pharma, Inc. Date: August 2, 2024 By: /a/ Justin. J. File Justin J. File Acting Chief Executive Officer, Chief Financial Officer and Secretary